Please login to the form below
Lilly sponsors African-American diabetes campaign
Eli Lilly is sponsoring a diabetes campaign designed to target African-Americans featuring the Grammy Award-nominated soul singer Angie Stone as spokesperson
US-based pharmaceutical company Eli Lilly is sponsoring a diabetes campaign designed to target African-Americans and featuring the Grammy Award-nominated soul singer and songwriter Angie Stone as its spokesperson.
The effort is called 'Be Fearless in the FACE of Diabetes,' with FACE serving as an acronym for 'Fearless African-Americans Connected and Empowered.'
Stone, who was diagnosed with Type 2 diabetes eight years ago, will make appearances at events in Chicago to tell her personal story and participate in healthy cooking demonstrations.
The full campaign consists of 'a series of practical and sustainable programmes in local communities' that focus on areas of diabetes management such as nutrition and physical activity.
A Lilly-branded website offers information on diabetes, more about Stone's experience with the disease, and details about campaign events. The educational effort is a partnership between Lilly and national and local health advocacy organisations.
Share
Related Hub content
Subscribe to our email news alerts
- Pfizer’s RSV vaccine granted MHRA approval to protect infants and older adults
- Novavax’s updated COVID-19 vaccine granted Emergency Use Listing by WHO
- FDA to investigate risk of T-cell malignancy from CAR-T cell immunotherapies
- Boehringer Ingelheim and IBM announce AI antibody drug discovery partnership
- New blood test to reduce heart attacks and death rates in A&E heart patients
- Clairvoyant commercialisation
No results were found
PMHub
Aptus Health
Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...
Latest intelligence
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
- The problem with clinical trials (and how virtual insight-gathering can help)
- While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
- The rise of digital healthcare – fuelled by open innovation in healthtech hubs
- How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of drug development...
